Education
About Us
Working with TipRanks
Follow Us
Prostatype Genomics AB (SE:PROGEN)
:PROGEN
RESEARCH TOOLSreports
PROGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr0.82 - kr20.05
Previous CloseN/A
Volume7.01K
Average Volume (3M)324.54K
Market Cap
€35.45M
Enterprise Valuekr25.18M
Total Cash (Recent Filing)€11.69M
Total Debt (Recent Filing)€666.42K
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Nov 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding37,000,263
10 Day Avg. Volume182,958
30 Day Avg. Volume324,535
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
PROGEN FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was kr0.82 and its highest was kr20.05 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is €35.45M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Nov 07, 2025 which is in 90 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Jul 23, 2025. The company reported -kr0.646 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.646.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 37,000,263 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -kr0.646 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in SE:PROGEN
Company Description
Prostatype Genomics AB
Prostatype Genomics AB (PROGEN) is a biotechnology company specializing in the development and commercialization of precision diagnostic tests for prostate cancer. The company's flagship product, Prostatype, is a gene expression test designed to assess the aggressiveness of prostate cancer, aiding clinicians in making more informed treatment decisions. Prostatype Genomics operates in the healthcare and life sciences sectors, focusing on improving patient outcomes through innovative genomic solutions.
Technical Analysis
Aino Health AB
―
Scandinavian ChemoTech AB Class B
―
ProstaLund AB
―
Stayble Therapeutics AB
―
Scandinavian Real Heart AB
―